EVO101
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atopic Dermatitis Eczema
Conditions
Atopic Dermatitis Eczema
Trial Timeline
Sep 27, 2022 → Jul 27, 2023
NCT ID
NCT05579899About EVO101
EVO101 is a phase 2 stage product being developed by Evommune for Atopic Dermatitis Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT05579899. Target conditions include Atopic Dermatitis Eczema.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06645821 | Phase 1 | Recruiting |
| NCT05579899 | Phase 2 | Completed |
Competing Products
20 competing products in Atopic Dermatitis Eczema